We have been over this already. Aclarubicin suffers the same...

We have been over this already. Aclarubicin suffers the same issue that bisantrene does as a substitute for doxorubicin - no clinician will switch. Bisantrene works as well or even better than doxorubicin (according to the Phase 3 breast cancer trial) yet we can’t get any clinician interested in switching over to using it. For better or worse, any solution to the doxorubicin cardiotoxicity problem is going to require making doxorubicin safer and better, not finding a better anthracycline.

Neefjes and his team have been trying to get aclarubicin off the ground for more than a decade with little success to date. In my opinion this is a shame, but this is the reality of clinical cancer research these days.

Oh for those wondering a couple of different groups have tried combining aclarubicin with doxorubicin in preclinical studies and in both cases aclarubicin was found to interfere with the cancer killing effect of doxorubicin.